Teva Pharmaceutical Industries Limited American Depositary Shar — Cash Flow (NYSE:TEVA) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends Documents

Cash from operating activities 1.22 B798 M1.59 B1.37 B1.25 B1.65 B 1.9 B Cash from investing activities 863 M1.52 B656 M968 M792 M737 M 38 M Cash from financing activities -1.89 B-2.17 B-1.49 B-1.91 B-1.79 B-2.15 B -401 M Free cash flow 638 M236 M1.04 B842 M749 M1.15 B 1.35 B

News

J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down

TEVA Stock Alert: What to Know as Teva Therapeutics' Scores FDA Approval for Schizophrenia Treament

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

Teva: 'Hold' On FDA Approval Of Weltruza And Pivot To Growth Strategy (TEVA)

Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives - Slideshow (NYSE:TEVA) 2026-10-09

Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript

FDA Approves Teva's New Once-Monthly Schizophrenia Injection

J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?

Teva, Already Up 26% This Year, Surges Again On First-Of-Its-Kind Approval

Teva Pharmaceuticals Receives FDA Approval Of WELTRUZA For Extended-Release Injectable Suspension For The Treatment Of Schizophrenia In Adults

Teva Pharma Presents New Ecopipam Data Highlighting Potential Benefits For Pediatric Tourette Syndrome Patients At MDS 2026

Teva Pharma Says Journal Of Child Neurology Publishes Comprehensive Review Examining Dopamine Pathways In Tourette Syndrome And Therapeutic Potential Of Ecopipam For Treatment Of Pediatric Patients With Tourette Syndrome